Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis

Detalles Bibliográficos
Autores principales: Cerchione, Claudio, Peluso, Ilaria, Nappi, Davide, Pareto, Anna Emanuele, Picardi, Marco, Martinelli, Vincenzo, Pane, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334413/
https://www.ncbi.nlm.nih.gov/pubmed/28197723
http://dx.doi.org/10.1007/s00277-017-2938-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334413/
https://www.ncbi.nlm.nih.gov/pubmed/28197723
http://dx.doi.org/10.1007/s00277-017-2938-5

Ejemplares similares